Higano CS, et al. Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. ASCO-GU 2019, abstract 256.
Adjuvant pembrolizumab versus observatie bij spierinvasief urotheelcarcinoom
feb 2025 | Immuuntherapie, Uro-oncologie